Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Convertible Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Employee Advances	Treasury Stock	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2011	$ 369	$ 11,284	$ 15,110,343		$ (3,419,715)	$ (14,559,209)	$ (2,856,928)
Beginning Balance, Shares at Dec. 31, 2011	368,862	11,283,830			1,179,212
Stock-based compensation			556,148				556,148
Warrants issued to 2012 private placement investors
Issuance of Series B preferred stock as payment-in-kind for dividend, Amount	26		243,975				244,001
Issuance of Series B preferred stock as payment-in-kind for dividend, Shares	25,823
Cashless exercise of warrants into common stock, Amount		1,466	(1,466)
Cashless exercise of warrants into common stock, Shares		1,465,578
Exercise of stock options into common stock, Amount		8	26,654				26,662
Exercise of stock options into common stock, Shares		8,332
Reclassification of employee advances partially collateralized by common stock (see note )				(156,468)			(156,468)
Provision to establish reserve against employee advances				137,610			137,610
Contractual dividends on Series B convertible preferred stock						(261,084)	(261,084)
Deemed dividends on redeemable Series C preferred stock						(433,606)	(433,606)
Warrants issued as debt discount in connection with notes payable
Issuance of common stock and warrants for cash, Amount		117	524,887				525,004
Issuance of common stock and warrants for cash, Shares		116,670
Cashless exercise of stock options into common stock, Amount		156	(156)
Cashless exercise of stock options into common stock, Shares		155,987
Imputed value of services contributed
Change in fair value of collateral securing employee advances							137,610
Net loss						(5,574,775)	(5,574,775)
Ending Balance, Amount at Dec. 31, 2012	395	13,031	16,460,385	(18,858)	(3,419,715)	(20,828,674)	(7,793,436)
Ending Balance, Shares at Dec. 31, 2012	394,685	13,030,397			1,179,212
Stock-based compensation			558,286				558,286
Warrants issued to 2012 private placement investors			487,200				487,200
Issuance of Series B preferred stock as payment-in-kind for dividend, Amount	27		261,057				261,084
Issuance of Series B preferred stock as payment-in-kind for dividend, Shares	27,630
Cashless exercise of warrants into common stock, Amount		10,342	(10,342)
Cashless exercise of warrants into common stock, Shares		10,342,931
Contractual dividends on Series B convertible preferred stock						(279,380)	(279,380)
Beneficial conversion feature and deemed dividend on Series B convertible preferred stock			1,532,722			(1,532,722)
Warrants issued as debt discount in connection with notes payable			403,300				403,300
Conversion of notes and accounts payable into common stock and warrants, Amount		833	3,625,067				3,625,900
Conversion of notes and accounts payable into common stock and warrants, Shares		833,000
Issuance of common stock and warrants for cash, Amount		3,502	3,498,473				3,501,975
Issuance of common stock and warrants for cash, Shares		3,501,975
Imputed value of services contributed			350,000				350,000
Change in fair value of collateral securing employee advances				9,857			9,857
Net loss						(5,489,892)	(5,489,892)
Ending Balance, Amount at Dec. 31, 2013	$ 422	$ 27,708	$ 27,166,147	$ (9,001)	$ (3,419,715)	$ (28,130,668)	$ (4,365,107)
Ending Balance, Shares at Dec. 31, 2013	422,315	27,708,303			1,179,212